Carina Schmidt has been appointed as the Chairperson of Lipigon Pharmaceuticals, she succeeds Gisela Sitbon. Carina has, as CEO of Athera, hands on experience in bringing a pre-clinical asset into late stage clinical development in the cardiometabolic field. She will therefore provide invaluable guidance as support for coming preclinical and clinical stages. With her experience she will help guide Lipigon into clinical development.
“We are very happy to have such an experienced professional on the board. Carina will bring with her 35 years of life science experience. She has achieved great things with Athera Biotechnologies so today we are very pleased welcoming her to the Lipigon team”, said CEO Stefan K Nilsson.
About Lipigon Pharmaceuticals
Lipigon was founded by leading scientists in the field lipid biology. Lipigon is currently focusing on the discovery and development of first-in-class treatments for lipid related diseases in the orphan space. For more information please visit: www.lipigon.se
For further information, please contact:
Stefan K. Nilsson, CEO, Lipigon Pharmaceuticals
Tel: +46 70 578 17 68